Innoforce and dMed Collaborate to Accelerate the Development of Innovative Therapeutics

Innoforce and dMed Collaborate to Accelerate the Development of Innovative Therapeutics
News provided by
Share this article
Share this article
HANGZHOU, China and SHANGHAI, March 2, 2021 /PRNewswire/ -- Innoforce, a biopharmaceutical innovation enabling platform and PDMO (Partner Development and Manufacturing Organization), and dMed, a clinical CRO with strong presence in China and the US - the world's two largest pharmaceutical and drug development markets, have signed an agreement under which the two parties agreed to establish a partnership to identify, assess, and collaborate on the development of clinical-stage therapeutics.
Dr. Lingshi Tan, founder and CEO of dMed said, "Our partnership with Innoforce will provide a powerful avenue to help clinical-stage therapeutic development programs from small and medium companies and to accelerate the pace of clinical development."

Related Keywords

China ,Shanghai ,Lingshi ,Sichuan ,Hangzhou ,Zhejiang ,Chinese ,Yuling Li ,Goliang Yu ,Partner Development ,Innforce Cgtx Services ,Thermo Fisher ,Clinical Contract Research Organization ,Manufacturing Organization ,Thermo Fisher Biopharma Services Hangzhou ,Lingshi Tan ,Thermo Fisher Biopharma Services ,Hangzhou Airport Economic Zone ,Hangzhou Bay Biotech Valley ,Pharma Intelligence ,Innoforce ,சீனா ,ஷாங்காய் ,ஸிச்வாந் ,ஜெஜியாங் ,சீன ,கூட்டாளர் வளர்ச்சி ,தெர்மோ மீனவர் ,மருத்துவ ஒப்பந்த ஆராய்ச்சி ஆர்கநைஸேஶந் ,உற்பத்தி ஆர்கநைஸேஶந் ,பார்மா உளவுத்துறை ,